메뉴 건너뛰기




Volumn 6, Issue 8, 2011, Pages 1400-1406

An open-label, multicenter, three-stage, phase II study of S-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer

Author keywords

Cisplatin; Clinical trial; Fluoropyrimidines; Lung cancer; Non small cell; S 1

Indexed keywords

CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

EID: 80051781864     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820d7805     Document Type: Article
Times cited : (16)

References (36)
  • 1
    • 0003432464 scopus 로고    scopus 로고
    • Cancer Facts & Figures 2009 Atlanta GA: American Cancer Society Available at Accessed October 17 2009
    • American Cancer Society. Cancer Facts & Figures 2009. Atlanta, GA: American Cancer Society; 2009. Available at: downloads/STT/500809web.pdf. Accessed October 17, 2009.
    • (2009) American Cancer Society
  • 3
    • 84855706212 scopus 로고    scopus 로고
    • NCCN clinical practice guidelines in oncology: Non-small cell lung cancer
    • Available at Accessed April 20, 2010.
    • NCCN Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer. National Comprehensive Cancer Network, V.2.2010. Available at: http://www.nccn.org/professionals/physician-gls/PDF/nscl.pdf. Accessed April 20, 2010.
    • (2010) National Comprehensive Cancer Network V 2
  • 4
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    • Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
    • (2008) J. Clin. Oncol. , vol.26 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    Von Pawel, J.3
  • 5
    • 65449177682 scopus 로고    scopus 로고
    • Thymidylate synthase dihydropyrimidine dehydrogenase orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis
    • Fukui Y, Oka T, Nagayama S, et al. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med 2008;22:709-716.
    • (2008) Int. J. Mol. Med. , vol.22 , pp. 709-716
    • Fukui, Y.1    Oka, T.2    Nagayama, S.3
  • 6
    • 4944261919 scopus 로고    scopus 로고
    • Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors
    • Fukushima M, Morita M, Ikeda K, et al. Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int J Mol Med 2003;12:839-844.
    • (2003) Int. J. Mol. Med. , vol.12 , pp. 839-844
    • Fukushima, M.1    Morita, M.2    Ikeda, K.3
  • 7
    • 0030815235 scopus 로고    scopus 로고
    • Concurrent 5-fluorouracil leucovorin etoposide cisplatin and radiotherapy for locally advanced non-small cell lung cancer
    • Yang CT, Chang WC, Chen LH, et al. Concurrent 5-fluorouracil, leucovorin, etoposide, cisplatin and radiotherapy for locally advanced non-small cell lung cancer. Changgeng Yi Xue Za Zhi 1997;20:187-194.
    • (1997) Changgeng Yi Xue Za Zhi. , vol.20 , pp. 187-194
    • Yang, C.T.1    Chang, W.C.2    Chen, L.H.3
  • 9
    • 10144246570 scopus 로고    scopus 로고
    • Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer
    • Crawford J, O'Rourke M, Schiller JH, et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 1996;14:2774-2784. (Pubitemid 26329664)
    • (1996) Journal of Clinical Oncology , vol.14 , Issue.10 , pp. 2774-2784
    • Crawford, J.1    O'Rourke, M.2    Schiller, J.H.3
  • 11
    • 80051801304 scopus 로고    scopus 로고
    • P53 status predicts the efficacy of postoperative oral administration of tegafur FT for completely resected non-small cell lung cancer NSCLC meeting abstract
    • Tanaka F, Yanagihara K, Ohtake Y, et al. p53 status predicts the efficacy of postoperative oral administration of tegafur (FT) for completely resected non-small cell lung cancer (NSCLC) (Meeting abstract). Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1997;16:A1746.
    • (1997) Proceedings of the Annual Meeting of the American Society of Clinical Oncology , vol.16
    • Tanaka, F.1    Yanagihara, K.2    Ohtake, Y.3
  • 12
    • 0033861835 scopus 로고    scopus 로고
    • Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: A randomized study on 70 patients
    • Xu G, Rong T, Lin P. Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: a randomized study on 70 patients. Chin Med J (Engl) 2000;113:617-620. (Pubitemid 30622443)
    • (2000) Chinese Medical Journal , vol.113 , Issue.7 , pp. 617-620
    • Xu, G.1    Rong, T.2    Lin, P.3
  • 13
    • 0031717342 scopus 로고    scopus 로고
    • Advantage of post-operative oral administration of UFT (Tegafur and Uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC)
    • DOI 10.1016/S1010-7940(98)00186-9, PII S1010794098001869
    • Tanaka F, Miyahara R, Ohtake Y, et al. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 1998;14:256-262. (Pubitemid 28417078)
    • (1998) European Journal of Cardio-thoracic Surgery , vol.14 , Issue.3 , pp. 256-262
    • Tanaka, F.1    Miyahara, R.2    Ohtake, Y.3    Yanagihara, K.4    Fukuse, T.5    Hitomi, S.6    Wada, H.7
  • 14
    • 0029915893 scopus 로고    scopus 로고
    • Adjuvant chemotherapy after complete resection in non-small-cell lung cancer
    • Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol 1996;14:1048-1054. (Pubitemid 26105508)
    • (1996) Journal of Clinical Oncology , vol.14 , Issue.4 , pp. 1048-1054
    • Wada, H.1    Hitomi, S.2    Teramatsu, T.3
  • 15
    • 0032921664 scopus 로고    scopus 로고
    • Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (Non- small cell lung cancer): A randomized clinical trial
    • DOI 10.1016/S1010-7940(99)00031-7, PII S1010794099000317
    • Wada H, Miyahara R, Tanaka F, et al. Postoperative adjuvant chemotherapy with PVM (Cisplatin- Vindesine- Mitomycin C) and UFT (Uracil- Tegafur) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). Eur J Cardiothorac Surg 1999;15:438-443. (Pubitemid 29210345)
    • (1999) European Journal of Cardio-thoracic Surgery , vol.15 , Issue.4 , pp. 438-443
    • Wada, H.1    Miyahara, R.2    Tanaka, F.3    Hitomi, S.4
  • 16
    • 77953462607 scopus 로고    scopus 로고
    • A pilot phase II study of capecitabine with carboplatin in patients with advanced nonsmall cell lung cancer
    • Sagar B, Estaphan F, Spell D.W, et al. A pilot phase II study of capecitabine with carboplatin in patients with advanced nonsmall cell lung cancer Int. J. Oncol. 2009 6-17
    • (2009) Int. J. Oncol. , pp. 6-17
    • Sagar, B.1    Estaphan, F.2    Spell, D.W.3
  • 17
    • 0029835349 scopus 로고    scopus 로고
    • Development of a novel form of an oral 5-fluorouracil derivative S-1 directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
    • Shirasaka T, Shimamoto Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-557.
    • (1996) Anticancer Drugs , vol.7 , pp. 548-557
    • Shirasaka, T.1    Shimamoto, Y.2    Ohshimo, H.3
  • 18
    • 0023250474 scopus 로고
    • Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts
    • Tatsumi K, Fukushima M, Shirasaka T, et al. Inhibitory effect of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987;78:748-755. (Pubitemid 17132408)
    • (1987) Japanese Journal of Cancer Research , vol.78 , Issue.7 , pp. 748-755
    • Tatsumi, K.1    Fukushima, M.2    Shirasaka, T.3    Fujii, S.4
  • 19
    • 0035964611 scopus 로고    scopus 로고
    • S-1 Cooperative Study Group Lung Cancer Working Group Phase II study of S-1 a novel oral fluorouracil in advanced non-small-cell lung cancer
    • Kawahara M, Furuse K, Segawa Y, et al; S-1 Cooperative Study Group (Lung Cancer Working Group). Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001;85:939-943.
    • (2001) Br. J. Cancer , vol.85 , pp. 939-943
    • Kawahara, M.1    Furuse, K.2    Segawa, Y.3
  • 20
    • 9744222663 scopus 로고    scopus 로고
    • S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: A multi-institutional phase II trial
    • DOI 10.1158/1078-0432.CCR-04-1200
    • Ichinose Y, Yoshimori K, Sakai H, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004;10:7860-7864. (Pubitemid 39587524)
    • (2004) Clinical Cancer Research , vol.10 , Issue.23 , pp. 7860-7864
    • Ichinose, Y.1    Yoshimori, K.2    Sakai, H.3    Nakai, Y.4    Sugiura, T.5    Kawahara, M.6    Niitani, H.7
  • 21
    • 27244440600 scopus 로고    scopus 로고
    • Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma
    • Ajani JA, Faust J, Ikeda K, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005;23:6957-6965.
    • (2005) J. Clin. Oncol. , vol.23 , pp. 6957-6965
    • Ajani, J.A.1    Faust, J.2    Ikeda, K.3
  • 22
    • 0024536437 scopus 로고
    • Optimal two-stage designs for phase II clinical trials
    • DOI 10.1016/0197-2456(89)90015-9
    • Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10. (Pubitemid 19099520)
    • (1989) Controlled Clinical Trials , vol.10 , Issue.1 , pp. 1-10
    • Simon, R.1
  • 24
    • 52649124206 scopus 로고    scopus 로고
    • Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: West japan thoracic oncology group 3505
    • Okamoto I, Nishimura T, Miyazaki M, et al. Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: West Japan Thoracic Oncology Group 3505. Clin Cancer Res 2008;14:5250-5254.
    • (2008) Clin. Cancer Res. , vol.14 , pp. 5250-5254
    • Okamoto, I.1    Nishimura, T.2    Miyazaki, M.3
  • 26
    • 77951813096 scopus 로고    scopus 로고
    • A multi-institution phase I II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer
    • Kubota K, Sakai H, Yamamoto N, et al. A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:702-706.
    • (2010) J. Thorac. Oncol. , vol.5 , pp. 702-706
    • Kubota, K.1    Sakai, H.2    Yamamoto, N.3
  • 27
    • 77951792883 scopus 로고    scopus 로고
    • Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naive patients with advanced non-small cell lung cancer
    • Satouchi M, Kotani Y, Katakami N, et al. Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naive patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:696-701.
    • (2010) J. Thorac. Oncol. , vol.5 , pp. 696-701
    • Satouchi, M.1    Kotani, Y.2    Katakami, N.3
  • 30
    • 0031804718 scopus 로고    scopus 로고
    • Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer
    • Zalcberg J, Millward M, Bishop J, et al. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 1998;16: 1948-1953.
    • (1998) J. Clin. Oncol. , vol.16 , pp. 1948-1953
    • Zalcberg, J.1    Millward, M.2    Bishop, J.3
  • 32
    • 36048982143 scopus 로고    scopus 로고
    • Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer
    • DOI 10.1200/JCO.2007.12.3026
    • Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743-4750. (Pubitemid 350086476)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.30 , pp. 4743-4750
    • Herbst, R.S.1    O'Neill, V.J.2    Fehrenbacher, L.3    Belani, C.P.4    Bonomi, P.D.5    Hart, L.6    Melnyk, O.7    Ramies, D.8    Lin, M.9    Sandler, A.10
  • 35
    • 33846257239 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells
    • DOI 10.1158/1535-7163.MCT-06-0419
    • Lee J-H, Park J-H, Jung Y, et al. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther 2006;5:3085-3095. (Pubitemid 46092050)
    • (2006) Molecular Cancer Therapeutics , vol.5 , Issue.12 , pp. 3085-3095
    • Lee, J.-H.1    Park, J.-H.2    Jung, Y.3    Kim, J.-H.4    Jong, H.-S.5    Kim, T.-Y.6    Bang, Y.-J.7
  • 36
    • 70349446637 scopus 로고    scopus 로고
    • S-1: A new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer
    • Okamoto I, Fukuoka M. S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2009;10:290-294.
    • (2009) Clin. Lung Cancer , vol.10 , pp. 290-294
    • Okamoto, I.1    Fukuoka, M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.